Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01832220 · ClinicalTrials.gov registry record
Genomic Research in Alpha-1 Antitrypsin Deficiency
A clinical trial, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 140
- Enrollment target
NCT01832220 is a clinical trial that has completed, run by University of Pittsburgh. The registered enrollment target is 140 participants.
The verdict
NCT01832220 has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 140 participants
- Enrollment target
Study Summary
This project is designed to examine the interaction between the microflora in the lower airway and the concentration of a serum protein called alpha-1 antitrypsin. The hypothesis is that alpha-1 antitrypsin impacts the diversity and content of the lower airway microflora, resulting in a less inflammatory airway. The Specific Aims are: 1. To compare the lower respiratory tract microbiome and virome population diversity and content in age and GOLD stage matched PiZZ individuals not receiving augmentation therapy, PiZZ individuals on augmentation therapy, PiMZ individuals not receiving augmentation therapy, and PiMM individuals with chronic obstructive pulmonary disease (COPD). 2. Determine correlations between bronchoalveolar lavage (BAL) and peripheral blood gene expression patterns and patterns in lung microbial and viral populations across all cohorts. 3. Correlate the presence or absence of computed tomography (CT) bronchiectasis and bronchiolectasis with patterns in the microbiome population diversity and content. 4. To identify and define novel molecular phenotypes of Alpha-1 Antitrypsin Deficiency (AATD) based on computational integration of clinical, transcriptomic, and microbiome data.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2013-05 |
| Est. Completion | 2015-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01832220
The ClinicalTrials.gov registry entry for NCT01832220 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01832220 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01832220 about?
NCT01832220 is a clinical study titled "Genomic Research in Alpha-1 Antitrypsin Deficiency". This project is designed to examine the interaction between the microflora in the lower airway and the concentration of a serum protein called alpha-1 antitrypsin. The hypothesis is that alpha-1 antitrypsin impacts the diversity and content of the lower airway microflora, resulting in a less inflamm...
What is the current status of trial NCT01832220?
This trial is currently completed. The enrollment target is 140 participants. The study started on 2013-05. Estimated completion is 2015-09.
Who is sponsoring clinical trial NCT01832220?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.